Management Team

Dr. Phillip Schwartz – CEO

Dr. Schwartz has more than twenty years of biotech and pharmaceutical industry experience. He has served as CEO and director of the board of director of Entera since its inception in 2010. Previously he held multiple positions in medical affairs, business development and clinical trial development at Serono and served as manager of clinical affairs at Endo Pharmaceuticals. He served as consultant to more than 20 large biotech and pharmaceutical companies and a number of venture capital firms. Dr Schwartz has multiple publications in tier one peer reviewed journals and has presented papers at numerous international conferences. Dr. Schwartz completed his BA in psychology and architecture at Columbia University. He then studied and worked in neurobiology with Nobel Laureate Professor Torsten Wiesel of the Rockefeller University. After completing his project, Dr. Schwartz studied immunology with Professor Irun Cohen at the Weizmann Institute, receiving his MSc. in 1991. In 1997 Dr. Schwartz received his Ph.D. in neurobiology/development/oncology from Harvard Medical School.

Dr. Arthur Santora - CMO

Dr. Santora has more than 30 years of experience in the biotech industry. He has spent the majority of his career in the clinical research team at Merck, where he was the lead clinical research physician responsible for much of the clinical development of Fosamax® (alendronate sodium), one of the world's most prescribed osteoporosis treatments. Dr. Santora was closely involved in the clinical development of Merck’s once-weekly Fosamax Plus D (alendronate sodium/ vitamin D3 combination tablets), the first drug/vitamin combination tablet in the US. His position when he retired from Merck in 2017 was as Scientific Associate Vice President of Clinical Research, where he was directly responsible for the technical and scientific support for all clinical research of Fosamax/Fosamax plus D and contributed to the development of many other osteoporosis and endocrine marketed and investigational drugs. Dr. Santora started his career at the FDA after completing an Endocrinology and Metabolism fellowship at the NIH Clinical Center in Bethesda, MD. He received an M.D. and Ph.D. in biochemistry from Emory University in Atlanta.

Dr. Hillel Galitzer – COO

Dr. Galitzer has more than ten years of experience in medical research and molecular biology and was mentored by two world renowned researchers in the field of PTH and calcium regulation. He has served as COO since February 2014, and on partial time as Director of Scientific Development since July 2012. Between August 2010 and February 2014 Dr. Galitzer was an analyst and COO for Hadasit Bio Holdings Ltd., a publicly traded company on the TASE and OTC markets. Dr. Galitzer is the co-founder and Chief Operating Officer of Optivasive Inc. He has written numerous publications in tier one peer reviewed articles and has lectured and presented in international conferences and universities. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, and his M.B.A. from Bar-Ilan University in Israel.

Mira Rosenzweig- CFO

Ms. Rosenzweig has over 15 years of experience in financial management. Ms. Rosenzweig has served as CFO of Entera since May 2014. Previously, from September 2008 to November 2011 Ms. Rosenzweig served as the Vice President and Chief Financial Officer of Camtek Ltd., traded on , Nasdaq and TASE. From August 2001 to August 2008, Ms. Rosenzweig served as Director of Finance and in various other positions for Elron Electronic Industries Ltd., traded on the TASE and previously on Nasdaq. Ms. Rosenzweig is a CPA (Israel) and holds a B.A. in Accounting and Economics from the University of Haifa, Israel.

Dr. Roger Garceau - Chief Development Advisor

Dr. Garceau has more than 30 years of broad pharmaceutical industry experience and has served as a director since March 2016 and as our Chief Development Advisor since December 2016. Prior to joining Entera, Dr. Garceau served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. since December 2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals was acquired by Shire plc. Previously, Dr. Garceau has also served in several managerial positions with NPS Pharmaceuticals, Inc., Sanofi-aventis and Pharmacia Corporation. Dr Garceau has been a non-executive director of Enterome SA since December 2016. He is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. Dr. Garceau holds B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University of Massachusetts Medical School.